Oral paclitaxel with immunotherapy and SBRT before surgery for older adults with lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years of age or older.
- You have been diagnosed with non-small cell lung cancer that has not spread beyond the lung area (stage IIA to IIIB).
- You are healthy enough to have surgery and have good organ function (such as adequate blood cell counts, liver and kidney function).
- Your cancer does not have specific genetic changes (EGFR, ALK, ROS1) that would require targeted therapy.
- You have not had prior lung surgery, chest radiation, or systemic cancer treatment.
- You do not have active autoimmune disease, serious infections, or other conditions that would make the treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
This trial tests whether a pill form of paclitaxel (a chemotherapy drug) given before surgery can help treat non-small cell lung cancer in adults aged 70–85. The goal is to shrink the tumor before removing it surgically, which may improve outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.